Plocamium Global Insights

One of the most significant effects of the merger will be the integration of both companies’ manufacturing capabilities. Mallinckrodt, historically known for its expertise in specialty branded and generic drugs, brings...

Meta’s ongoing discussions with Apollo Global Management to secure a $35 billion financing package for U.S. data centers offer a glimpse into a larger capital cycle—one that extends far beyond tech and into the very...

Plocamium has previously discussed energy transition as part of a broader industrial transformation—one that does not operate in isolation but rather converges with advancements in healthcare and manufacturing. Energy...

We’ve long recognized that manufacturing is not just an operational necessity—it is the foundation of sustainable growth, resilience, and innovation. Healthcare companies that embrace this reality will define the future...

The healthcare industry is undergoing a profound transformation, shaped by stringent regulatory requirements, shifting demographic trends, and the increasing need for outsourced production. Contract development and...

Manufacturing is no longer just about scale—it's about adaptability. AI-driven drug repurposing is reshaping how CDMOs and CMOs operate, demanding faster, more flexible production cycles that cater to a future...

Fosun’s decision to exit Gland Pharma comes at a time when scrutiny of China-dependent supply chains has never been higher. Acquiring Gland Pharma represents more than just buying a profitable CDMO (Contract Development...

Healthcare facilities management is a critical but often underappreciated component of the industry’s infrastructure. Hospitals, clinics, and long-term care facilities rely on effective operations to maintain...

In a recent discussion, Lynn Good, CEO of Duke Energy, offered a strategic perspective on the latest round of proposed tariffs. Rather than viewing them as purely protectionist, Good framed them as a negotiation tool...

The climate-tech sector is undergoing a massive shift, with M&A leading the charge. Last year alone, we saw nearly $80 billion in climate-tech deals across more than 300 transactions, with over 60% focused on clean...

Novartis’ recent $3.1 billion acquisition of Anthos Therapeutics is more than just a transaction—it’s a strategic pipeline reintegration move that could signal a new era in biopharma M&A. The deal brings abelacimab...

How the Trump administration's deregulation push could reshape healthcare policy, from Medicaid home-health rules to private equity investment opportunities in the sector.

France is making a high-stakes move in the global AI race, announcing a staggering €109 billion in AI investments. This initiative, championed by President Emmanuel Macron, isn’t just about economic growth—it’s about...

This isn’t just another healthcare technology deal—it’s a microcosm of how today’s private markets are pushing the boundaries of leverage and financial structuring. But the key question remains: Is this the right kind...

Pfizer Inc. (NYSE: PFE) stands at a financial crossroads, balancing its capital allocation priorities between business development (BD), debt management, and shareholder returns.